Global Pharma Investment in China Surges to $48.5 Billion in First Half of 2025, Doubling 2024 Total
核心洞察
Global pharmaceutical companies invested $48.5 billion in partnerships with Chinese biotechs during the first half of 2025, surpassing the entire 2024 total of $44.8 billion.
The surge included 61 deals in H1 2025, with 16 exceeding $1 billion in value and five surpassing $3 billion, indicating a trend toward larger, more strategic partnerships.
U.S. companies dominated the deal landscape, representing 61% of partnerships compared to 37% in 2024, with oncology remaining the top therapeutic area.
Global pharmaceutical companies have dramatically accelerated their investment in Chinese biotechnology partnerships, committing $48.5 billion in the first half of 2025 alone—a figure that already exceeds the entire 2024 total of $44.8 billion. This unprecedented surge in cross-border collaboration signals a fundamental shift in how multinational pharma companies are approaching innovation sourcing and market expansion strategies.
Record-Breaking Deal Activity
According to IQVIA analysis, the pharmaceutical industry struck 61 partnership deals with Chinese biotechs during the first six months of 2025, with projections suggesting the full-year total will easily surpass the 100 agreements signed in 2024. The scale and value of these partnerships have grown substantially, with 16 deals exceeding $1 billion in value—matching the entire year's count for 2024 in just six months.
The trend toward mega-deals is particularly striking, with five partnerships in H1 2025 surpassing $3 billion in value, compared to only three such deals in all of 2024. This concentration of large-scale investments reflects growing confidence in Chinese biotech capabilities and the strategic importance of accessing China's healthcare market.
U.S. Companies Lead Partnership Surge
American pharmaceutical companies have emerged as the dominant force in China partnerships, representing 61% of all deals in the first half of 2025—a significant increase from 37% in 2024. This shift indicates a strategic pivot by U.S. pharma toward Chinese innovation as a source of cost-effective drug development.
"In recent years, global biopharma companies have become more willing to invest in Chinese-originated therapies as a way to source efficient and cost-effective innovation," IQVIA noted in their analysis. "In return, Chinese firms have received global validation for their novel assets and technologies as well as a steady cash flow to fund further development."
Major Deal Highlights
Several landmark partnerships have defined the first half of 2025. Pfizer's agreement with 3SBio (搜索) stands out as the largest single transaction, featuring $1.25 billion upfront, $100 million in equity investment, and up to $4.8 billion in milestone payments. The deal provides Pfizer access to SSGJ-707, a Phase III-ready bispecific antibody targeting PD-1 (搜索) and VEGF (搜索) for treatment of non-small cell lung cancer (搜索), metastatic colorectal cancer (搜索), and gynecological tumors (搜索).
AstraZeneca also made significant commitments, offering $4.68 billion in deal value to Harbour BioMed (搜索) for multi-specific antibodies targeting immunology and oncology applications. These partnerships demonstrate the pharmaceutical industry's focus on accessing advanced therapeutic platforms developed by Chinese biotechs.
Therapeutic Focus and Deal Structure
Oncology continues to dominate partnership activity, maintaining its position as the number one indication area for several consecutive years. Immunological and inflammatory diseases are also experiencing growth as partnership targets, reflecting the breadth of Chinese biotech capabilities across multiple therapeutic areas.
Deal structures have evolved toward a more risk-managed approach, with pharmaceutical companies favoring heavily backloaded agreements. Under this model, Chinese biotechs conduct early-stage research domestically to generate initial clinical data, while their pharma partners wait until assets are de-risked before committing larger investments.
Geopolitical Considerations
Despite growing geopolitical tensions between the U.S. and China, partnership activity has continued to accelerate. IQVIA's analysis suggests "these cross-border partnerships will continue to thrive in the near future," based on first-half data trends.
However, concerns about long-term competitive dynamics persist. Former FDA commissioner Scott Gottlieb recently warned in JAMA that "if we fail to halt the drift of biomedical discovery toward China, we risk ceding a strategic technological advantage that may prove all but impossible to win back." Gottlieb, now a senior fellow at the American Enterprise Institute, highlighted the strategic implications of this investment surge for U.S. biomedical leadership.
The dramatic increase in pharmaceutical investment in Chinese biotechs reflects both the maturation of China's innovation ecosystem and the industry's need for cost-effective drug development solutions. As regulatory reforms continue to foster international collaboration and China's healthcare infrastructure expands, this trend appears positioned to reshape global pharmaceutical R&D strategies for years to come.